摘要
The COVID-19 pandemic,caused by SARS-CoV-2,continues to rage in many countries,straining health systems and economies.Vaccines protect against severe disease and death and are considered central to ending the pandemic.COVID-19 vaccines(and SARS-CoV-2 infection)elicit antibodies that are directed against the viral spike(S)protein and neutralize the virus.However,the emergence of SARS-CoV-2 variants with S protein mutations that confer resistance to neutralization might compromise vaccine efficacy[1].
基金
S.P.acknowledges funding by BMBF(01KI2006D,01KI20328A,01KI20396,01KX2021)
the Ministry for Science and Culture of Lower Saxony(14-76103-184,MWK HZI COVID-19)
the German Research Foundation(DFG,PO 716/11-1,PO 716/14-1)
M.S.W.received unrestricted funding from Sartorius AG,Lung Research.H.-M.J.received funding from BMBF(01KI2043,NaFoUniMedCovid19-COVIM:01KX2021)
Bavarian State Ministry for Science and the Arts and Deutsche Forschungsgemeinschaft(DFG)through the research training groups RTG1660 and TRR130.G.B.acknowledges funding from the German Center for Infection Research(grant no 80018019238).
